SLMAP and EPO Genetic Polymorphism in Diabetic Retinopathy
Evaluation of the Relationship Between SLMAP and EPO Genetic Polymorphism and the Risk of Diabetic Retinopathy in Egyptian Diabetic Patients: A Case-Control Study
1 other identifier
observational
180
1 country
1
Brief Summary
A case-control study to assess the association between the risk of diabetic retinopathy in Egyptians and genetic polymorphism of both EPO and SLMAP genes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started May 2022
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 19, 2022
CompletedFirst Posted
Study publicly available on registry
April 25, 2022
CompletedStudy Start
First participant enrolled
May 20, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 30, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2023
CompletedFebruary 7, 2024
February 1, 2024
12 months
April 19, 2022
February 6, 2024
Conditions
Outcome Measures
Primary Outcomes (2)
Association of SLMAP gene polymorphism and the risk of confirmed diabetic retinopathy diagnosis
the odds ratio of being diagnosed with diabetic retinopathy in those with SLMAP rs17058639 single nucleotide polymorphism compared to wild type
At baseline (upon confirmed diagnosis of diabetic retinopathy)
Association of EPO gene polymorphism and the risk of confirmed diabetic retinopathy diagnosis
The odds ratio of being diagnosed with diabetic retinopathy in those with EPO rs551238 single nucleotide polymorphism compared to wild type
At baseline (upon confirmed diagnosis of diabetic retinopathy)
Secondary Outcomes (1)
The association of confounding factors on the incidence of diabetic retinopathy
At baseline
Study Arms (2)
cases
diabetic patients suffering from clinically confirmed diabetic retinopathy
controls
matched (based on gender and duration of diabetes) diabetic patients free from diabetic retinopathy will be recruited.
Interventions
Presence of EPO gene SNP rs551238 and SLMAP rs17058639 gene polymorphisms
Eligibility Criteria
All diabetic patients registered to the outpatient clinic of the Endocrinology Unit will be assessed for eligibility followed by screening for diabetic retinopathy by fundoscopic examination Those with diabetic retinopathy will be assigned to the case group while matched diabetic patients free from diabetic retinopathy will be assigned to the control group.
You may qualify if:
- Age \>30-60
- Type 2 DM
- Duration of diabetes from 5-10 years
- Egyptian patients
You may not qualify if:
- Other ophthalmic diseases not related to diabetes
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Ain Shams University Hospitals
Cairo, Abbasseya, Egypt
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Lamiaa M El Wakeel, PhD
Faculty of Pharmacy, Ain Shams University
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal investigator
Study Record Dates
First Submitted
April 19, 2022
First Posted
April 25, 2022
Study Start
May 20, 2022
Primary Completion
April 30, 2023
Study Completion
June 30, 2023
Last Updated
February 7, 2024
Record last verified: 2024-02